alzheimer
-
Nutrition & Diet for Elderly
Glucosamine Supplements Could Accelerate Alzheimer’s Progression
The popular over-the-counter joint health supplement glucosamine has long been a staple in medicine cabinets across the globe, frequently utilized…
Read More » -
Alzheimer’s & Dementia Care
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The recent findings, unveiled at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2026) in Copenhagen, represent a…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity as the First Non-Antipsychotic Treatment for Agitation Associated with Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel therapeutic option for the…
Read More » -
Alzheimer’s & Dementia Care
Alzheimer’s and Brain Awareness Month 2024: A Global Call to Action for Research and Cognitive Health
June serves as a critical junction for the global medical community and the millions of families affected by neurodegenerative conditions,…
Read More » -
Alzheimer’s & Dementia Care
Real-world study of Zunveyl reveals promising provider-reported outcomes for Alzheimer’s patients in long-term care settings
Top-line results from the BEACON real-world study have shed new light on the clinical utility of Zunveyl (benzgalantamine), an oral…
Read More » -
Alzheimer’s & Dementia Care
FDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to remlifanserin, an investigational therapeutic agent currently…
Read More » -
Alzheimer’s & Dementia Care
Patients can now skip infusions at hospital during early treatment for Alzheimer’s disease as the therapeutic landscape shifts toward at-home care.
In a landmark development for neurology and patient care, the U.S. Food and Drug Administration (FDA) has expanded the authorization…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for…
Read More » -
Alzheimer’s & Dementia Care
June: A Pivotal Month for Alzheimer’s and Brain Awareness, Catalyzing Research and Action Against a Global Health Challenge
June marks a critical period for global public health as the Alzheimer’s Association spearheads Alzheimer’s & Brain Awareness Month, a…
Read More » -
Alzheimer’s & Dementia Care
Zunveyl (benzgalantamine) Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Study
Top-line data from the BEACON study, a real-world observational study, indicate that Zunveyl (benzgalantamine) was associated with provider-reported improvements across…
Read More »
